HEMATOCASE

Myeloid lineage switching as escape mechanism to chimeric antigen receptor T-cell therapy in precursor B-ALL with ZNF384-TCF3 fusion: A case report

BJH - volume 13, issue 3, may 2022

B. Brichard MD, PhD, B. De Moerloose MD, PhD, C. De Crem MD, M. de Ville de Goyet MD, PhD, M. Hofmans MD, PhD, V. Mondelaers MD

SUMMARY

Acute leukaemia with ZNF384-TCF3 fusion is considered high risk in contemporary frontline treatment protocols and will be treated by Hematopoietic Stem Cell Transplantation (HSCT) or Chimeric Antigen Receptor T-cell (CART) treatment in first complete remission. Although current cytogenetic and molecular work-up of newly diagnosed paediatric acute lymphoblastic leukaemia (ALL) includes the identification of the TCF3-ZNF384 fusion, this case underscores the importance of including this information in the choice of bridging therapy and the timing of CART treatment, as the high cytokine levels during high grade Cytokine Release Syndrome (CRS) might drive ALL cells to lineage switching.

(BELG J HEMATOL 2022;13(3):128–32)

Read more

Leishmaniasis: A potential lymphoma Mimicker

BJH - volume 13, issue 2, march 2022

B. Heyrman MD, G. Van den Eynden MD, PhD, N. Granacher MD, S. Heyman MD

SUMMARY

In Belgium, a 53-year old Caucasian man presented at the haematology consultations with weight loss and night sweats in the last six weeks. Apart from a cholecystectomy and appendectomy, he had no medical history. He had no pets; his last journey abroad was to Spain eight months ago. On physical examination, splenomegaly was noted. Blood testing revealed a microcytic anaemia (Hb 9.3g/dl), leukopenia (2.63x10E9/L) with normal formula, normal liver testing and crp of 47.9g/dl. Serologic testing for HIV, CMV, HepB, HepC, and Toxoplasma was negative. Trephine biopsy was normal. PET/CT scan demonstrated splenomegaly with high FDG-avidity. Splenectomy was performed. Small granules (amastygotes) were seen by the pathologist suggestive for Leishmaniasis. Serologic testing and PCR confirmed the diagnosis. He was subsequently treated with liposomal amphotericin B. Our patient is now in optimal condition. Earlier serologic testing for this rare tropical disease in a non-endemic region could have prevented splenectomy.

(BELG J HEMATOL 2022;13(2):92–4)

Read more

Advanced systemic mastocytosis: An uncommon cause of chronic diarrhoea and weight loss

BJH - volume 13, issue 2, march 2022

B. Sciot MD, L. Michaux MD, PhD, N. Boeckx MD, PhD, P. Vandenberghe MD, PhD, T. Devos MD, PhD, T. Tousseyn MD, PhD

SUMMARY

Introduction: Advanced systemic mastocytosis is a rare myeloproliferative disorder of mast cells, damaging the function of various organs and tissues. The diagnosis can be challenging due to its protean manifestations and rareness. Treatment options have improved over the last years. Currently, avapritinib, a novel tyrosine kinase inhibitor with activity against p.D816V mutated KIT, is under investigation.

Case: We report a case of a 64-year old man with chronic diarrhoea, fatigue, weight loss and ascites with hepatomegaly, developing an upper gastro-intestinal bleeding with multiple duodenal ulcers. Diagnostic work-up revealed hepatosplenomegaly and portal hypertension, a vertebral compression fracture and multiple 18F-FDG avid supra- and infradiaphragmatic lymph nodes and bone marrow. Based on the 2016 WHO criteria of systemic mastocytosis, and a concomitant chronic myelomonocytic leukaemia, the diagnosis of an aggressive systemic mastocytosis with an associated haematological neoplasm was made. The patient was consecutively treated with midostaurin, cladribine and avapritinib, the latter inducing a complete biochemical and molecular response.

Conclusion: This case illustrates the challenging clinical presentation of systemic mastocytosis. A deep response to avapritinib was observed despite prior use of midostaurin and cladribine, underlining its promise in advanced systemic mastocytosis.

(BELG J HEMATOL 2022;13(2):84–91)

Read more

Primary gastric plasmacytoma: Case report of a rare plasma cell neoplasm

BJH - volume 12, issue 8, december 2021

A. De Wind MD, PhD, A. Lemmers MD, PhD, D. Bron MD, PhD, M. Roelandt MD, M. Vercuyssen MD, N. Meuleman MD, PhD, O. Rizzo MD, P. Eisendrath MD, PhD

SUMMARY

A 46-year-old woman presented with epigastric pain and weight loss for over a year. An upper endoscopy was performed and showed a polypoid lesion in the antropyloric region. Immuno-pathological report revealed a proliferation of plasma cell nature. The whole work-up including complete blood test, bone marrow biopsy and 18FDG-PET-CT did not detect extra gastric lesion of multiple myeloma. The diagnosis of extramedullary plasmacytoma of the stomach was established. Radiotherapy (44 Gy) with a curative intent was administered but the control biopsy showed residual disease. Endoscopic submucosal dissection was then performed with R0 resection (negative margins) leading to complete remission.

(BELG J HEMATOL 2021;12(8):349–52)

Read more

Clinical case: High grade “triple hit” Lymphoma

BJH - volume 12, issue 7, november 2021

B. Lambert MD, G. Sqalli MD, J. Simar MD, L. Dierge PharmD, T. Connerotte MD, T. Roy

SUMMARY

We report the case of a 64-year-old patient, known for follicular lymphoma, admitted with facial paralysis accompanied by acute cervicobrachialgia. A lumbar puncture revealed the presence of centroblastic lymphoma cells whose clonal nature was confirmed by immunophenotyping. The histological examination of a lymph node biopsy was consistent with Burkitt-like high-grade lymphoma. Cytogenetic analysis showed the concomitant presence of a rearrangement of MYC as well as of BCL2 and BCL6. A final diagnosis of “triple-hit” high-grade B cell lymphoma (HGBL) was thus made. This entity belongs to the HGBL category of the WHO 2016 classification and shares characteristics with diffuse large B-cell lymphoma and Burkitt lymphoma. The diagnosis of this entity can be complex, in particular in view of a significant morphological variability. The cytogenetic work-up is thus essential for the differential diagnosis.

(BELG J HEMATOL 2021;12(7):318–22)

Read more

Recurrent deep venous thrombo-embolism in an obese anticoagulated patient

BJH - volume 12, issue 7, november 2021

L. Rozen PhD , N. Ghorra , S. Eeckhoudt PhD

SUMMARY

Deep venous thrombosis (DVT) is a medical emergency requiring immediate anticoagulant treatment to prevent further clot formation and pulmonary thrombo-embolism. We present here the case of a patient affected by class I obesity who suffered from recurrent DVT despite anticoagulation with rivaroxaban.1 After a switch to VKA, it appeared that the patient also presented resistance to vitamin K antagonists (VKA). Through this case, we would like to highlight the factors that must be taken into account when initiating and monitoring an anticoagulation therapy, including obesity and VKA resistance.

(BELG J HEMATOL 2021;12(7):323–6)

Read more

EBV-induced double hit transformation of splenic (marginal zone) lymphoma, in a patient with a chronic Hepatitis B virus hepatitis

BJH - volume 12, issue 6, october 2021

C. Deroose MD, PhD, D. Dierickx MD, PhD, L. Jannis MD, L. Michaux MD, PhD, L. Waumans MD, T. Tousseyn MD, PhD

SUMMARY

We report a case of an EBV-induced large-cell transformation of a splenic marginal zone lymphoma in an 81-year-old female with a simultaneous finding of hepatitis B viral infection.

(BELG J HEMATOL 2021;12(6):275-9)

Read more
X